NCT06589791View on ClinicalTrials.gov

A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists

CompletedOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)
Interventions
OTHER

No treatment given

Online self-completion survey

Trial Locations (1)

Unknown

Novo Nordisk Shanghai Pharmaceuticals Co., Ltd, Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06589791 - A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists | Biotech Hunter | Biotech Hunter